The Benefit of Detecting Reduced Intracellular B12 Activity through Newborn Screening Remains Unclear

Abstract

pen AccessArticle
by Stella Knöpfli,Bernadette Goeschl,Maximilian Zeyda,Anna Baghdasaryan,Margot Baumgartner-Kaut,Matthias R. Baumgartner,Marion Herle,Julian Margreitter,Martin Poms,Saskia B. Wortmann,Vassiliki Konstantopoulou andMartina Huemer
Int. J. Neonatal Screen. 2024, 10(2), 40; https://doi.org/10.3390/ijns10020040 - 18 Jun 2024
Viewed by 1138
Abstract
Vitamin B12 (B12) deficiency (B12D) can have detrimental effects on early growth and development. The Austrian newborn screening (NBS) program targets inborn errors of cobalamin metabolism and also detects B12D. Of 59 included neonates with B12D suspected by NBS, B12D was not further investigated in 16 (27%) retrospectively identified cases, not confirmed in 28 (48%), and confirmed in 15 (25%) cases. NBS and recall biomarkers were recorded. Age at sampling of the dried blood spots for NBS and the 1st-tier methionine/phenylalanine ratio were the strongest parameters to predict B12D (67.4% correct allocations). No differences between cases with confirmed, unconfirmed, or unknown B12D or differences to norms were observed for growth and psychomotor development (Vineland III scales, phone interviews with parents of children between months 10 and 14 of life). B12 intake was below recommendations in most mothers. NBS can detect reduced intracellular B12 activity. No advantage of NBS detection and treatment regarding infant cognitive development or growth could be proven. Since conspicuous NBS findings cannot be ignored, and to prevent exposing newborns to invasive diagnostics, assessment of maternal B12 status during pregnancy seems advisable. Full article